Elidel Sales Fall In Q3 On Fewer U.S. Prescriptions, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of Novartis' eczema treatment Elidel (pimecrolimus) fell 36% to $53 mil. in the third quarter on fewer U.S. prescriptions, Novartis reported Oct. 18
You may also be interested in...
Elidel Labeling (Clarification)
An Oct. 18 1story in "The Pink Sheet" DAILY on declining sales for Novartis' eczema treatment Elidel (pimecrolimus) did not describe with sufficient clarity the status of discussions between the firm and FDA on labeling changes
Elidel Labeling (Clarification)
An Oct. 18 1story in "The Pink Sheet" DAILY on declining sales for Novartis' eczema treatment Elidel (pimecrolimus) did not describe with sufficient clarity the status of discussions between the firm and FDA on labeling changes
Novartis' Elidel, Fujisawa's Protopic To Add "Black Box" On Cancer Risk
Novartis expects labeling negotiations will begin within the next few weeks and says a "black box" is unjustified. A medication guide will also be required for the eczema treatments, FDA says.